Information Provided By: 
Fly News Breaks for June 3, 2019
GBT
Jun 3, 2019 | 07:22 EDT
Wedbush analyst Liana Moussatos raised her price target for Global Blood Therapeutics to $107 from $95 given reduced clinical, regulatory, commercial and manufacturing risk along with sufficient cash for initial U.S. launch, strong IP and upside potential from multiple potentially material catalysts and as more investors appreciate that FDA is not solely focused on VOC as a primary endpoint for SCD. The analyst reiterates an Outperform rating on the shares.
News For GBT From the Last 2 Days
There are no results for your query GBT
